Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2022 | Insights into a novel antibody-drug conjugate in myeloma: HDP-101

Hans Lee • 25 Oct 2022
SOHO Italy 2022
Multiple Myeloma Antibodies Belantamab mafodotin HDP-101

Hans Lee, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into a novel BCMA-targeting antibody-drug conjugate (ADC) known as HDP-101, and its potential use in the treatment of multiple myeloma. Dr Lee highlights the reduced side effects that may be observed with this agent, as well as the need for more research on its safety and efficacy. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hans Lee

2:57
LINKER-MM1: promising safety and efficacy of linvoseltamab in R/R multiple myeloma
Hans Lee • 10 Dec 2023
5:14
LINKER-MM1: linvoseltamab in patients with R/R multiple myeloma
Hans Lee • 4 Jun 2023
2:12
Risk of infection and mitigation strategies in patients with myeloma treated with bispecifics
Hans Lee • 4 Jun 2023
1:47
Role of BCMA-targeting ADCs in the management of myeloma
Hans Lee • 4 Jun 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals